Ischemia With No Blockage: What INOCA Means for Women

Ischemia means the heart muscle is not getting enough blood. INOCA means that is happening without a blockage to point to. Both halves are real.

INOCA stands for Ischemia with Non-Obstructive Coronary Arteries. The word ischemia is the critical distinction from its more acute counterpart: this is not a heart attack. There is no troponin elevation, no permanent myocardial injury in the acute sense. There is chest pain, reduced exercise tolerance, objective evidence of reduced myocardial perfusion, and coronary arteries that look normal on angiography. The patient is told the arteries are clean and is sent home, sometimes with a diagnosis of atypical chest pain or anxiety. The WISE study data tells a different story.

The Mechanism

To understand why ischemia occurs without obstructive coronary disease, the physiology of the coronary circulation needs two separate frames. The first frame is the epicardial arteries, the vessels visible on standard angiography. These range from roughly 1.5 to 4 millimeters in diameter and supply the large distributing branches of the coronary tree. When these are stenosed above 70%, the reduction in flow is significant enough to produce symptoms and objective ischemia under stress. This is the obstructive coronary artery disease that standard stress tests and angiography are designed to find.

The second frame is the microvasculature: arterioles, precapillary sphincters, and capillaries below the resolution limit of standard angiography, typically less than 0.5 millimeters in diameter. These vessels are responsible for regulating approximately 70 to 80% of total coronary vascular resistance. When a person exercises or undergoes pharmacologic stress, the normal microvasculature dilates to three to five times its resting diameter, increasing coronary blood flow proportionally. This vasodilatory reserve is what allows the heart to meet higher oxygen demands during physical activity. When microvascular dysfunction is present, this reserve is impaired: the vessels fail to dilate on demand, dilate incompletely, or actively constrict. The result is relative underperfusion of the downstream myocardium during conditions of increased demand. The epicardial arteries on the angiogram are open. The problem is one level deeper.

The second primary mechanism is coronary vasospasm, in which an epicardial artery undergoes focal, intense, transient constriction. This is distinct from microvascular dysfunction in that the problem is in a visible vessel, but it is dynamic: the spasm occurs and resolves within minutes, typically before the patient reaches the catheterization lab. The resting angiogram shows a normal-caliber artery. The event that produced symptoms was not visible at the time of the procedure.

These two mechanisms often coexist in the same patient. The INOCA patient may have both impaired microvascular reserve and episodic vasospasm superimposed, which is why identifying the dominant endotype, and whether both are present, requires deliberate physiologic assessment rather than a single test.

What the Evidence Shows

The Women’s Ischemia Syndrome Evaluation (WISE), an NHLBI-sponsored prospective cohort study conducted across four academic centers in the United States, is the foundational dataset for INOCA. WISE enrolled women referred for cardiac catheterization for suspected ischemic heart disease and followed them longitudinally. Bairey Merz, Shaw, Reis, and colleagues published the primary outcomes across multiple papers, with findings extending through the early 2000s and subsequent substudies continuing for over a decade.

The core WISE finding was that women with chest pain and non-obstructive coronary arteries on catheterization were not a low-risk group. At follow-up, documented in Gulati and colleagues (NEJM, 2006) and extended in Pepine and colleagues, these women had annual major adverse cardiovascular event rates of approximately 2.5%, with elevated rates of MI, stroke, heart failure hospitalization, and cardiovascular death compared with women without ischemia. Quality of life scores were substantially impaired, and rates of repeat hospitalization and emergency department visits were high. The interpretation that a clean angiogram meant no cardiac problem was incorrect for this population.

The WISE-CVD extension study quantified coronary flow reserve using intracoronary Doppler in a subset of women with non-obstructive coronary arteries. Approximately 47% had coronary flow reserve below 2.5, indicating significant microvascular dysfunction. A reduced coronary flow reserve in this cohort was independently associated with worse cardiovascular outcomes at follow-up. This established a mechanistic link between the physiologic abnormality and the adverse prognosis, not merely a symptomatic association.

The CorMicA trial (Ford, Berry, and colleagues, JACC, 2018) is the most important interventional evidence for INOCA. This randomized trial enrolled 151 patients with angina and non-obstructive coronary arteries at cardiac catheterization. All patients underwent invasive physiologic testing with coronary flow reserve, index of microcirculatory resistance, and acetylcholine provocation. Patients were randomized to disclosure of the test results with endotype-specific treatment assignment, or to standard care without disclosure of physiologic results. At six months, the disclosed group had significantly better angina scores on the Seattle Angina Questionnaire (SAQ) and better quality-of-life outcomes. The benefit was driven by patients who received endotype-specific therapy: calcium channel blockers for vasospastic endotype, ACE inhibitors and beta-blockers for microvascular endotype. The CorMicA trial is currently the strongest evidence that identifying the INOCA endotype and treating accordingly improves measurable patient outcomes.

The SPIRRIT-HFpEF trial context is relevant here because coronary microvascular dysfunction has been identified as a mechanistic contributor to heart failure with preserved ejection fraction (HFpEF), a condition also over-represented in women. Shah and colleagues have published data linking reduced coronary flow reserve to worse outcomes in HFpEF patients, creating a mechanistic bridge between microvascular dysfunction detected in the INOCA workup and longer-term cardiac functional consequences. This suggests that addressing microvascular dysfunction may have implications beyond angina management.

For vasospasm specifically, the COVADIS group (Beltrame et al., European Heart Journal, 2017) formalized diagnostic criteria for vasospastic angina: symptoms at rest, particularly nocturnally or triggered by cold; transient ECG changes during episodes; and angiographic confirmation of coronary spasm, either spontaneous or provoked. The COVADIS criteria are now the reference framework for diagnosing the vasospastic endotype and are incorporated into ESC guidance on chronic coronary syndromes.

Why INOCA Disproportionately Affects Women

INOCA is not exclusively a female condition, but it disproportionately affects women, and the sex-specific biology is mechanistically relevant.

Estrogen has vasodilatory and endothelial-protective effects. Post-menopausal loss of estrogen is associated with worsening microvascular function. The WISE cohort identified a significant inflection point in ischemic symptom burden around menopause, with pre-menopausal women having better microvascular function than post-menopausal women matched for risk factors. This biological gradient is supported by experimental data showing estrogen-mediated upregulation of endothelial nitric oxide synthase, the enzyme responsible for producing the vasodilatory signal nitric oxide in the vessel wall.

Women’s coronary circulation is, on average, smaller in absolute dimension relative to body surface area than men’s, even after adjusting for cardiac size. Smaller absolute vessel caliber alters the hemodynamic relationship between epicardial and microvascular resistance, making the microvascular contribution to total resistance proportionally larger. This structural difference means that microvascular dysfunction has a larger relative impact on total coronary flow in women than in men.

Inflammatory markers and autoimmune activation are more prevalent in women and are associated with endothelial dysfunction and microvascular disease. Bairey Merz and colleagues have published detailed mechanisms linking inflammatory state, including elevated C-reactive protein and autoimmune markers, to impaired coronary vasoreactivity in women with non-obstructive coronary disease. The immune-vascular axis may represent a pathway by which systemic inflammatory conditions such as lupus, rheumatoid arthritis, and scleroderma, all more prevalent in women, contribute to coronary microvascular pathology.

Psychological stress and trauma exposure are also associated with INOCA risk and may operate partly through autonomic dysregulation that impairs microvascular vasoreactivity. Vaccarino and colleagues have published data on adverse childhood experiences and coronary vasomotor dysfunction in women, raising the possibility that stress-mediated autonomic effects on the coronary microvasculature represent a partly separate mechanism from traditional risk factor-mediated endothelial disease.

INOCA Versus MINOCA

The distinction is acute versus chronic injury. MINOCA is a confirmed acute MI: rising and falling troponin, ischemic evidence on ECG or imaging, non-obstructive angiogram. It requires immediate workup to determine etiology and carries short-term mortality risk in the range of 2 to 5% at one year per registry data. INOCA is a chronic ischemic syndrome: recurrent symptoms, objective ischemia on noninvasive or invasive testing, and non-obstructive arteries, without the acute injury marker.

The mechanisms overlap: both can involve vasospasm and microvascular dysfunction. But the MINOCA patient had a completed infarction with myocardial cell death; the INOCA patient has ongoing ischemia without completed infarction. The distinction determines urgency, specific workup priorities, and whether troponin management and hospitalization-level protocols apply. A patient with INOCA may eventually present with MINOCA if an acute event occurs, which is part of why managing the chronic condition matters for event prevention.

The Non-Invasive Diagnostic Path: When Invasive Testing Is Not Available

Invasive coronary physiology testing, performed through catheterization, remains the diagnostic gold standard for INOCA because it allows direct measurement of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) in individual vessels. But it carries procedural risk, requires catheterization laboratory availability, and is not always the appropriate first step — particularly for patients who declined catheterization or in centers where physiologic assessment during angiography is not routinely performed. Non-invasive imaging has advanced substantially and can provide meaningful diagnostic information before any catheterization is considered.

Cardiac magnetic resonance imaging with stress vasodilator agents — adenosine or regadenoson — can detect subendocardial perfusion defects that characterize microvascular disease. The subendocardium is supplied by the deepest coronary microvasculature and is the territory most sensitive to impaired microvascular perfusion. Stress CMR myocardial perfusion mapping, using quantitative pixel-wise analysis, now achieves diagnostic accuracy for coronary microvascular dysfunction that approaches invasive CFR measurement. A 2022 meta-analysis by Kotecha and colleagues in the European Heart Journal reported sensitivity of 0.89 and specificity of 0.87 for quantitative CMR perfusion versus invasive CFR as the reference standard — performance sufficient to guide initial management decisions without catheterization. 3 / Early

Cardiac positron emission tomography with rubidium-82 or nitrogen-13 ammonia tracers measures absolute myocardial blood flow in mL per minute per gram of tissue under rest and vasodilator stress. This allows calculation of CFR as the ratio of stress to rest blood flow — the same physiologic metric measured invasively. A CFR at or above 2.0 is generally considered normal; values below 2.0, particularly below 1.7, are consistent with coronary microvascular dysfunction at a level associated with adverse prognosis in the WISE and other registry cohorts. Cardiac PET achieves this measurement non-invasively and has the highest diagnostic accuracy among non-invasive modalities for CMD, though availability is limited to centers with dedicated cardiac PET infrastructure.

Coronary computed tomography angiography with CT myocardial perfusion provides simultaneous anatomic coronary assessment and functional perfusion information in a single study. This is particularly useful when the distinction between obstructive and non-obstructive disease has not yet been established, as CT angiography can rule out significant coronary stenosis while CT perfusion identifies regional perfusion deficits that would not be explained by obstructive anatomy.

The practical implication for patients is that a referral for stress cardiac MRI or cardiac PET can establish objective ischemia without obstructive anatomy, providing the diagnostic foundation for symptom attribution and treatment guidance even when invasive testing is deferred or unavailable.

What to Do This Week

1. If you have had a catheterization for chest pain that showed clean arteries but no physiologic testing, ask your cardiologist whether coronary flow reserve, index of microcirculatory resistance, or vasospasm provocation testing was measured. If not, ask whether repeat catheterization with physiologic assessment or referral to a center that performs it is appropriate for your case.

2. Bring objective evidence to every appointment: any stress test showing perfusion abnormality, any nuclear imaging result, any stress CMR or PET report. Objective ischemia on noninvasive testing, even without an obstructive lesion to correlate it to, is clinically significant and supports the case for further physiologic evaluation.

3. Ask directly about endotype: “Do I have evidence of microvascular dysfunction, vasospasm, or both? How does that change my treatment?” If your cardiologist cannot answer that question, it means the endotype has not been determined, which is a gap in the workup, not a conclusion about your diagnosis.

4. Keep a symptom log: time of day, trigger (exertion versus rest), duration, associated symptoms, relief with sublingual nitroglycerin if you carry it. Rest-predominant and nocturnal patterns suggest vasospasm; exertional patterns suggest microvascular demand-failure. This information guides the diagnostic hypothesis before testing is ordered.

5. The ESC 2024 guidelines on chronic coronary syndromes explicitly address non-obstructive coronary ischemia as a defined clinical entity with diagnostic and treatment recommendations. This framework is available in the published literature and is directly applicable if you encounter clinical resistance to the diagnosis.

INOCA is not a catch-all for unexplained chest pain. It is a physiologically defined ischemic syndrome with identifiable mechanisms, measurable abnormalities, and mechanism-specific treatments. The clean angiogram is the starting point of the INOCA evaluation, not its conclusion. What follows from that starting point, systematic physiologic assessment, endotype identification, and targeted treatment, is what converts a dismissive diagnosis into a plan with evidence behind it. The workup is what gets you from an unexplained symptom to a targeted answer.